Hepatitis C virus
is a positive‐sense RNA virus that is parenterally transmitted and is associated with chronic liver disease – fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. The virus infects an estimated 123 million individuals worldwide with 5 million new infections occurring per annum. The prevalence of the virus, and the persistent nature of the infection, has led to the prediction that it will become an ever‐increasing burden on global healthcare resources. There is no vaccine to prevent infection; however, treatment options, until recently limited to a combination of interferon and ribavirin, have been improved by the advent of direct‐acting antivirals. These therapeutic advances have been underpinned by recent developments in our understanding of the molecular biology of virus infection, which are described in this article. In particular, the establishment of a system for the study of the complete virus lifecycle in tissue culture has led to many major advances and provides opportunities for further therapeutic developments.
Key Concepts:
Hepatitis C virus
(HCV) is a major human pathogen infecting approximately 3% of the world population.
HCV causes chronic liver disease – fibrosis, cirrhosis and hepatocellular carcinoma.
HCV is a positive‐strand RNA virus that infects hepatocytes in the liver.
Recent developments in HCV biology have allowed a deeper understanding of mechanisms of replication and pathogenesis.
New direct‐acting antiviral compounds promise to improve therapeutic options.